Combo-vs-Mono Decision Aid for First-Line EGFR-Mutated NSCLC

A visit-time tablet tool that shows newly diagnosed EGFR-mutated lung cancer patients and their doctors the quantified choice between osimertinib alone or with chemotherapy: about 10 extra months of median survival versus severe side-effect risk doubling from 34% to 70%.